Combined Spinal-epidural Anesthesia for Cesarean Section Without Prophylactical Prehydration and Vasopressors
Launched by SHENZHEN PEOPLE'S HOSPITAL · Apr 12, 2018
Trial Information
Current as of May 14, 2025
Unknown status
Keywords
ClinConnect Summary
1. General: This was a single-centre randomized controlled trial performed at ShenZhen People's Hospital of Jinan University. Study protocol was approval was by the Ethics Committee of ShenZhen People's Hospital of Jinan University, ShenZhen, China (Permit No. SZY-00251, Chairperson Prof. Xiaofang Yu) on 8 February 2017. Pregnant women who were scheduled for cesarean section were recruited. Written informed consents were obtained from all patients. Women with cardiovascular disease, fetal abnormalities, placental abruption, placenta previa, placental abnormalities, sidewall placenta, abnorm...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant women who were scheduled for cesarean section.
- Exclusion Criteria:
- • Women with cardiovascular disease, fetal abnormalities, placental abruption, placenta previa, placental abnormalities, sidewall placenta, abnormal fetal heart rate and spinal anesthesia contraindications.
About Shenzhen People's Hospital
Shenzhen People's Hospital is a leading medical institution in China, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital is committed to improving patient outcomes by exploring novel therapies and treatment modalities across various medical fields. With a state-of-the-art facility and a team of experienced healthcare professionals, Shenzhen People's Hospital fosters a collaborative environment for clinical research, ensuring adherence to rigorous ethical standards and regulatory requirements. Their focus on patient-centered care and commitment to scientific advancement positions them as a key player in the landscape of medical research in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shenzhen, Guangdong, China
Patients applied
Trial Officials
Zhongjun Zhang, master
Study Director
ShenZhen People's Hospital of Jinan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials